Executive Summary
Today's digest covers 9 SEC filings, with 5 new entries and 4 for context, revealing a bifurcated M&A landscape. The most material developments are two transformative acquisitions: Nocopi Technologies' $2.65M purchase of Polymeric US, which more than triples its revenue base, and Ondas Holdings' acquisition of Omnisys, which adds over $100M in high-margin defense revenue.
However, the SPAC market shows significant stress, with GSR V Acquisition Corp. reporting a going concern warning and an accumulated deficit of $7.3M despite a $230M IPO. Period-over-period comparisons are limited as most filings are for newly formed SPACs, but the operational companies (Nocopi, Ondas) show strong forward-looking revenue growth. Insider activity is notable at Nocopi, where a new director and an affiliate purchased shares in a private placement, signaling confidence. Capital allocation is mixed, with Nocopi using a mix of cash and stock (dilutive) while Ondas pursues a high-growth, high-margin acquisition. The overarching theme is a 'haves vs. have-nots' dynamic: companies with clear operational targets (Nocopi, Ondas) are executing, while cash-rich SPACs face existential risks.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 8-K
Tracking the trend? Catch up on the prior US Merger & Acquisition SEC Filings digest from May 20, 2026.
Investment Signals (9)
- Nocopi Technologies ↓ (BULLISH)▲
Acquisition of Polymeric US triples revenue base (adding $5M+ TTM revenue) with historically attractive pre-tax margins; new director and affiliate purchased 133,334 shares each at $1.50/share in private placement
- Ondas Holdings ↓ (BULLISH)▲
Acquisition of Omnisys adds $100M+ in high-margin defense revenue over 2026-2027, transitioning from platform provider to integrated software-driven operator; Omnisys has profitable track record without external capital
- GSR V Acquisition Corp. ↓ (BEARISH)▲
IPO raised $230M but auditor flags substantial doubt about going concern due to $7.3M accumulated deficit and limited cash; SPAC has not commenced operations
- Patriot Acquisition Corp. ↓ (NEUTRAL)▲
SPAC raised $175M in trust with focus on fintech/specialty finance; experienced management team (ex-bank CEO) but no target yet; neutral catalyst
- Crown PropTech Acquisitions ↓ (MIXED)▲
Filed F-4 for business combination with Mkango Rare Earths; only $5.76M cash in trust vs. need for additional financing; geopolitical risks in Malawi and Poland
- Amanat Acquisition Corp. ↓ (BEARISH)▲
New $75M healthcare SPAC IPO; no target selected and no substantive discussions; high risk of failing to find deal within 18-24 months
- RYVYL Inc. ↓ (NEUTRAL)▲
Completed reverse merger with RTB Digital; post-merger shares outstanding ~5.8M; name and ticker changed to RTB; limited financial data but merger execution successful
- ARC Group Acquisition I Corp. ↓ (NEUTRAL)▲
Units begin separate trading May 28, 2026; provides liquidity event for early investors; no target yet
- Chenghe Acquisition III Co. ↓ (NEUTRAL)▲
Director resignation and replacement with experienced finance/tech executive; no financial impact but governance change
Risk Flags (8)
- GSR V Acquisition Corp./Going Concern↓ [HIGH RISK]▼
Auditor expresses substantial doubt about ability to continue as going concern; accumulated deficit $7.3M, shareholders' deficit $7.3M, and significant costs to pursue business combination
- Crown PropTech Acquisitions/Financing Risk↓ [HIGH RISK]▼
Only $5.76M cash in trust for business combination with Mkango; additional financing needed; geopolitical instability in Europe and Malawi
- Nocopi Technologies/Dilution↓ [MEDIUM RISK]▼
Issued 500,000 new shares (diluting existing holders by ~27% based on pre-deal share count); $0.75M equity component in acquisition
- Amanat Acquisition Corp./No Target↓ [MEDIUM RISK]▼
SPAC has no selected target and no substantive discussions; 18-24 month deadline to complete deal; risk of liquidation
- Patriot Acquisition Corp./No Target↓ [MEDIUM RISK]▼
$175M in trust but no business combination announced; SPAC market headwinds may make finding quality target difficult
- ARC Group Acquisition I Corp./No Target↓ [LOW RISK]▼
IPO completed but no target identified; separate trading may increase volatility
- Chenghe Acquisition III Co./Governance↓ [LOW RISK]▼
Director resignation with no reason cited; new director has no prior relationship with company; potential instability
- RYVYL Inc./Integration Risk↓ [MEDIUM RISK]▼
Reverse merger completed; combined entity renamed; integration of RTB Digital operations and culture may pose challenges
Opportunities (8)
- Nocopi Technologies/Revenue Growth↓ (OPPORTUNITY)◆
Acquisition adds $5M+ TTM revenue vs. pre-deal base of ~$1.5M; 3x revenue growth; Polymeric has 30-year history and top 10 customers with 5+ year relationships
- Ondas Holdings/Defense AI↓ (OPPORTUNITY)◆
Omnisys expects $100M+ revenue over 2026-2027 with high margins; BRO software is vendor-agnostic and serves NATO/allied defense; positions Ondas as pure-play defense AI
- Patriot Acquisition Corp./SPAC Arbitrage↓ (OPPORTUNITY)◆
$175M in trust at $10/unit; experienced management team with FIG focus; potential for value if quality target found; trade at trust value with upside optionality
- Crown PropTech Acquisitions/Rare Earths Play↓ (OPPORTUNITY)◆
Mkango owns Songwe Hill rare earths project in Malawi and Poland separation project; critical minerals theme; F-4 filed May 20, 2026; potential catalyst if SEC clears
- Amanat Acquisition Corp./Healthcare SPAC↓ (OPPORTUNITY)◆
$75M in trust; healthcare focus; Leerink Partners as underwriter; potential for quality biotech/healthcare target; early-stage opportunity
- ARC Group Acquisition I Corp./Liquidity Event↓ (OPPORTUNITY)◆
Separate trading of units begins May 28, 2026; allows investors to trade components (shares, warrants, rights) independently; potential for mispricing
- GSR V Acquisition Corp./Distressed SPAC↓ (OPPORTUNITY)◆
$230M in trust but going concern warning; if SPAC liquidates, shareholders may get ~$10/share; current price likely below trust value; potential arbitrage
- RYVYL Inc./Reverse Merger Completion↓ (OPPORTUNITY)◆
Merger closed successfully; Nasdaq listing approved; new ticker RTB; potential for re-rating if combined entity shows growth
Sector Themes (6)
- SPAC Market Stress◆
3 of 5 SPAC filings (GSR V, Crown PropTech, Amanat) show significant risks—going concern, lack of target, or financing gaps—indicating continued SPAC market distress and need for quality deal flow
- Defense Tech M&A Premium◆
Ondas Holdings' acquisition of Omnisys highlights growing M&A interest in AI-powered defense software; vendor-agnostic, multi-domain platforms command high valuations and revenue visibility
- Critical Minerals SPAC Activity◆
Crown PropTech's combination with Mkango Rare Earths reflects ongoing SPAC interest in critical minerals; geopolitical risks (Malawi, Poland) are key valuation factors
- Small-Cap Transformational M&A◆
Nocopi and Ondas both use M&A to fundamentally transform their business models (revenue 3x, platform to software); small caps using M&A as growth catalyst
- Healthcare SPAC Niche◆
Amanat's $75M healthcare SPAC IPO shows continued appetite for healthcare-focused blank check companies; Leerink Partners involvement signals institutional interest
- Reverse Merger Revival◆
RYVYL/RTB Digital reverse merger completed successfully; trend of companies using reverse mergers for faster public listing vs. traditional IPO
Watch List (8)
-
Separate trading of units begins May 28, 2026; monitor for price dislocations between units and components
-
F-4 filed May 20, 2026; SEC review process; shareholder vote; monitor for financing announcements and geopolitical developments in Malawi/Poland
-
Going concern warning; monitor for business combination announcement or liquidation; trust value vs. market price arbitrage opportunity
-
Post-acquisition integration; monitor Q2 2026 earnings for Polymeric revenue contribution and margin realization; insider buying pattern
-
Omnisys revenue ramp; monitor for defense contract announcements; $100M+ revenue target over 2026-2027 provides catalyst timeline
-
IPO closes May 20, 2026; monitor for target identification; healthcare sector focus may attract biotech targets
-
$175M in trust; monitor for business combination announcement; FIG sector focus; experienced management team
-
Post-merger trading under new ticker RTB; monitor for first combined earnings report; integration progress
Filing Analyses
(9)
21-05-2026
Nocopi Technologies acquired substantially all assets of Polymeric US, Inc. for $2.65 million, funded with $1.75M cash, $0.75M equity (500,000 shares at $1.50/share), and a $0.15M holdback. The acquisition more than triples Nocopi's revenue base, adding over $5M in trailing twelve-month revenue with historically attractive pre-tax margins. However, the company issued 500,000 new shares (diluting existing holders) and appointed Gregory S. Babe as Executive Director of Operations, who along with a Horizon Kinetics affiliate purchased 133,334 shares each at $1.50/share in a private placement.
- · Polymeric was founded in 1993 and has a 30-year operating history.
- · Top 10 customers have an average relationship tenure of more than 5 years.
- · Polymeric generated over $5M in revenue for the trailing twelve months ended March 31, 2026.
- · The acquisition more than triples Nocopi's revenue base.
- · Polymeric will continue to operate under its own brand out of its 25,000 sq ft facility in Kansas City, MO.
- · Gregory S. Babe brings over 40 years of leadership experience and a 'lean growth' philosophy.
- · The private placement involved 266,668 total shares at $1.50/share, raising approximately $400,000.
- · No specific pre-tax margin percentage was disclosed for Polymeric (only described as 'historically attractive').
21-05-2026
Patriot Acquisition Corp. closed the partial exercise of the underwriter's over-allotment option, selling an additional 1,500,000 units at $10.00 per unit for gross proceeds of $15,000,000, and simultaneously sold 75,000 additional private placement warrants for $75,000. Total gross proceeds from the IPO and over-allotment reached $175,000,000, with $175,875,000 now held in trust. The SPAC intends to focus on financial industry targets including fintech, specialty finance, and digital banking, but no business combination has been announced yet.
- · The SPAC's management team is led by Jack Kopnisky (CEO/Chairman) and Thomas Cestare (CFO/Vice Chairman).
- · The company intends to focus on the financial industry group (FIG Sector), specifically fee-based fintech, specialty finance, and digital banking.
- · Units began trading on Nasdaq on May 15, 2026 under ticker PTACU.
- · The registration statement was declared effective by the SEC on May 13, 2026.
- · No business combination has been identified or announced; the company remains a blank check company.
21-05-2026
Chenghe Acquisition III Co. announced the resignation of director Ningrong Liu effective May 18, 2026, with no disagreement cited, and the appointment of Zhong Li as an independent Class II director effective the same day. Mr. Li brings over 20 years of experience in finance, regulation, and technology, and will serve on the Audit, Compensation, and Nominating Committees. The filing contains no financial data or period-over-period comparisons.
- · Mr. Li has been designated as a Class II director and will serve until the expiration of that class term.
- · Mr. Li will enter into an indemnification agreement in substantially the same form as other non-employee directors.
- · Mr. Li is not party to any transaction requiring disclosure under Item 404(a) of Regulation S-K.
- · The company is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
21-05-2026
ARC Group Acquisition I Corp announced that holders of its units may elect to separately trade the Class A ordinary shares, warrants, and rights included in its units commencing on or about May 28, 2026. The company completed its initial public offering of 12,075,000 units on May 5 and May 7, 2026, including the full exercise of the underwriters' over-allotment option.
- · Separate trading of Class A ordinary shares, warrants, and rights begins on or about May 28, 2026.
- · Units not separated will continue to trade on NASDAQ under symbol ARCLU.
- · Class A ordinary shares will trade under ARCL, warrants under ARCLW, and rights under ARCLR.
- · The IPO included the full exercise of the underwriters' over-allotment option.
21-05-2026
GSR V Acquisition Corp. consummated its IPO on May 15, 2026, selling 23,000,000 units (including full exercise of the over-allotment option) at $10.00 per unit, generating gross proceeds of $230,000,000. Simultaneously, the company completed a private placement of 671,000 units to the sponsor and underwriters for $6,710,000. A total of $230,000,000 was deposited into a trust account, and the audited balance sheet shows total assets of $232,245,000 against total liabilities of $9,532,612. However, the independent auditor's report notes substantial doubt about the company's ability to continue as a going concern due to limited cash and the significant costs of pursuing a business combination, with an accumulated deficit of $7,279,655 and a shareholders' deficit of $7,287,612.
- · The company incorporated on July 23, 2025 and had not commenced operations as of May 15, 2026.
- · The underwriters fully exercised their over-allotment option to purchase 3,000,000 additional units.
- · Out of the $6,710,000 private placement proceeds, $5,400,000 was added to the trust account, $1,301,301 paid costs, and $8,699 is receivable from sponsor as an increase to shareholders' deficit.
- · Transaction costs include $4,025,000 cash underwriting fees, $9,200,000 deferred underwriting commissions (related party), and $657,301 other offering costs.
- · The audited balance sheet as of May 15, 2026 reports total assets of $232,245,000, total liabilities of $9,532,612, and total shareholders' deficit of $7,287,612.
- · Class A ordinary shares subject to possible redemption are valued at $230,000,000 (23,000,000 shares at $10.00 per share).
21-05-2026
Ondas Holdings Inc. (ONDS) announced the completion of its acquisition of 100% of Omnisys Ltd., an Israeli developer of AI-powered Battle Resource Optimization (BRO) software for multi-domain defense planning. The transaction transitions Ondas from a platform provider into a fully integrated, software-driven systems-of-systems operator, with BRO expected to serve as the central mission optimization layer across Ondas's autonomous systems. Omnisys expects more than $100 million in revenue with high margins over the course of 2026 and 2027, and has a long-standing track record of profitable operations without reliance on external capital.
- · BRO is a modular, scalable, and vendor-agnostic software suite integrating data from multiple sensors, platforms, and C2 systems using AI and operations research.
- · Omnisys has a global customer base spanning NATO and allied defense organizations.
- · BRO supports the full operational cycle: pre-mission planning, in-mission dynamic adaptation, and post-mission debriefing.
- · BRO operates as an intelligent command layer enabling closed-loop sense-decide-act operations across ISR, strike, electronic warfare, and air defense missions.
- · Omnisys has maintained a long-standing track record of profitable operations without reliance on external capital.
21-05-2026
Mkango Rare Earths Limited (MKAR) and Crown PropTech Acquisitions (CPTK) announced the filing of a registration statement on Form F-4 with the SEC on May 20, 2026, for their proposed business combination initially announced on July 3, 2025. The transaction is subject to SEC review, shareholder approvals, and customary closing conditions, with MKAR's shares expected to list on Nasdaq under symbols "MKAR" and "MKARW". CPTK has approximately $5.76 million cash in trust, but the filing highlights significant risks including potential failure to complete the combination, geopolitical instability in Europe, and the need for additional financing.
- · The registration statement on Form F-4 was filed on May 20, 2026.
- · The proposed business combination was initially announced on July 3, 2025.
- · MKAR owns the advanced stage Songwe Hill rare earths development project in Malawi and a proposed rare earths separation project in Pulawy, Poland.
- · Both the Songwe Hill and Pulawy projects have been selected as strategic projects under the European Union's Critical Raw Materials Act.
- · CPTK is a special purpose acquisition company incorporated in 2021.
- · The transaction is subject to approval by Mkango as shareholder of MKAR, approval by CPTK shareholders, and TSX Venture Exchange approval.
- · Risks include geopolitical instability in Europe, political and social risks in Malawi and Poland, and the need for additional financing.
21-05-2026
Amanat Acquisition Corp announced the pricing of its $75 million initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share, with shares expected to trade on Nasdaq under the ticker 'AMAN'. The SPAC intends to focus on healthcare or healthcare-related industries for a future business combination, but has not yet selected any specific target. The offering is expected to close on May 20, 2026, and Leerink Partners is the sole bookrunning manager.
- · The Company is a newly organized Cayman Islands exempted company and blank check company.
- · The registration statement was declared effective by the SEC on May 18, 2026.
- · The Company has not selected any specific business combination target and has not engaged in any substantive discussions with any target.
- · The Company's Board of Directors includes Dr. Sandeep C. Kulkarni, Dr. Pavan Cheruvu, Ms. Rakhi Kumar, Mr. Brad Middlekauff, and Mr. Patrick Crutcher.
- · The Company is sponsored by Amanat Sponsor Holdings LLC.
- · The underwriter has a 45-day option to purchase up to 1,125,000 additional shares to cover over-allotments.
21-05-2026
RYVYL Inc. completed its reverse merger with RTB Digital, Inc. on May 12, 2026, issuing 4,384,504 shares of common stock to former RTB shareholders and post-merger outstanding shares of approximately 5.8 million. The combined entity, renamed
- · The merger agreement was approved by Ryvyl stockholders on April 1, 2026.
- · Nasdaq approved listing of post-merger common stock on the Capital Market on May 11, 2026.
- · Name changed from 'Ryvyl Inc.' to 'RTB Digital, Inc.' effective May 11, 2026; trading symbol changed to 'RTB' on May 13, 2026.
- · Post-merger board has 7 members: James Heckman, Alykhan Madhavji, Walton Comer, Michael Alexander, David Bailey, Brett Moyer, Steven Fletcher.
- · Resignations of directors Gene Jones, Tod Browndorf, and George Oliva (Oliva remains as CAO) effective May 15, 2026.
- · Audit Committee: Steven Fletcher (Chair), Michael Alexander, Brett Moyer (all independent). Compensation Committee: Walton Comer (Chair), Steven Fletcher. Nominations Committee: David Bailey (Chair), Michael Alexander.
- · Indemnification agreements to be entered into with directors post-closing.
- · Total potential dilution from assumed securities: up to ~13.1 million additional shares (options 3.39M, warrants 2.07M, convertible debt 7.69M), compared to the 5.77M outstanding shares immediately after merger.
- · No registration rights for shares issued upon conversion of assumed convertible debt or warrants.
- · Geographic focus: San Diego, CA (principal executive offices).
Get daily alerts with 9 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 9 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US Merger & Acquisition SEC Filings
🇺🇸 More from United States
View all →May 28, 2026
US Pre-Market SEC Filings Roundup — May 28, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals